The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enough
Authors:
Open Access
- 1 May 2021
- journal article
- review article
- Published by Elsevier in Cytotherapy
- Vol. 23 (5) , 357-366
Abstract
No abstract availableKeywords
Funding Information
- School of Life Sciences, Arizona State University
- U.S. Food and Drug Administration
- Shanghai University
This publication has 10 references indexed in Scilit:
- CAR-NK cells: A promising cellular immunotherapy for cancerEBioMedicine, 2020
- Identifying the Risks of Unproven Regenerative Medicine TherapiesJAMA, 2020
- Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed “Stem Cell Treatments” for COVID-19Cell Stem Cell, 2020
- Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer ImmunotherapyCancers, 2020
- Gene-editing pipeline takes offNature Reviews Drug Discovery, 2020
- Engineering strategies to overcome the current roadblocks in CAR T cell therapyNature Reviews Clinical Oncology, 2019
- The INN global nomenclature of biological medicines: A continuous challengeBiologicals, 2019
- Cell, tissue and gene products with marketing authorization in 2018 worldwideCytotherapy, 2018
- Balancing Safety and Innovation for Cell-Based Regenerative MedicineNew England Journal of Medicine, 2018
- Unification of Protein Abundance Datasets Yields a Quantitative Saccharomyces cerevisiae ProteomeCell Systems, 2018